-- Data update for ongoing ACTengine(R) IMA200 clinical trial series 
      demonstrated first anti-tumor activity in heavily pre-treated solid 
      cancer patients during early phases of dose escalation 
 
   -- Next ACTengine(R) data update for dose levels 2 and 3 on track for H2 
      2021 
 
   -- Preclinical proof-of-concept for second TCR Bispecifics (TCER(R)) program 
      IMA402 against the frequently expressed cancer target PRAME announced 
 
   -- Cash and cash equivalents as well as other financial assets of $254.0 
      million (EUR216.7 million1) as of March 31, 2021 provide cash reach into 
      2023 
 
 
   Tuebingen, Germany and Houston, TX, May 18, 2021 -- Immatics 
https://www.globenewswire.com/Tracker?data=3OUW4XZ8xSsExWuKxufF3ErMWFHuOwSgi_aLjTH9VAIYz_GMBXP0W7aI8QxE9q_EC_oz_UudMLuCfXxBmsmc_w== 
N.V. 
https://www.globenewswire.com/Tracker?data=2Ld5_yepFxEA44Zrtj-fdOdDyGqVCxax2q4hFFrJtQ0bs51ZAnJD3Mcavwt5XO6Nz16HsH7AuSoxH5gSt_ujwg== 
(NASDAQ: IMTX; "Immatics"), a clinical-stage biopharmaceutical company 
active in the discovery and development of T cell redirecting cancer 
immunotherapies, today reported financial results and provided a 
business update for the quarter ended March 31, 2021. 
 
   "In the first quarter of 2021, we reported first anti-tumor activity at 
the initial dose levels of our ACTengine(R) IMA200 clinical trial series 
which indicates the potential of our engineered Adoptive Cell Therapy 
approach. We continue to scale up enrollment by initiating additional 
trial sites in the US and Europe -- and now look forward to treating 
patients at target dose levels and provide a next update in the second 
half of 2021," said Harpreet Singh, Ph.D., CEO of Immatics. "In addition, 
we are on track with our first clinical trial application for TCER(R) 
towards the end of this year. By engaging two therapeutic modalities, 
Adoptive Cell Therapy and TCR Bispecifics, we are aiming to address a 
broad cancer patient population with an urgent need for new therapeutic 
options." 
 
   First Quarter 2021 and Subsequent Company Progress 
 
   https://www.globenewswire.com/Tracker?data=Qltl875Ro9mO_PhzTX7wgqdTdLSUz0xY9tiL-oh4RUVpK6wXQdnsso4FITcELPQphvJvHj4gHd2Xz-cmT-qKB3YFpTrh469-1Qw0HNk_sFXcw0wPVVpawdBZS1QW078cH1X90KD0R3SN1bgB_yjQ5A== 
Adoptive Cell Therapy Programs 
 
 
   -- ACTengine(R) IMA200 series - Immatics provided a clinical data update 
      https://investors.immatics.com/news-releases/news-release-details/immatics-presents-data-update-dose-escalation-ongoing-actenginer 
      from three ongoing ACTengine(R) Phase 1 trials 
      https://investors.immatics.com/news-releases/news-release-details/immatics-presents-data-update-dose-escalation-ongoing-actenginer 
      for its engineered Adoptive Cell Therapy approach (also known as TCR-T) 
      in March. The combined data readout during early phases of dose 
      escalation for the ACTengine(R) programs, IMA201, IMA202 and IMA203, 
      indicated first anti-tumor activity with tumor shrinkage observed in 8 
      out of 10 patients including one unconfirmed partial response as of data 
      cut-off. This was consistent with the observed robust engraftment, 
      persistence and tumor infiltration of infused ACTengine(R) T cells. 
      Overall, the product candidates demonstrated a manageable safety and 
      tolerability profile. 
 
   -- The ACTengine(R) trials continue to recruit according to plan with eight 
      trial sites active in both Europe and the US. A data update is expected 
      in H2 2021 with additional patients being treated, including initial data 
      from patients treated at the target dose. 
 
   -- The fourth program of the ACTengine(R) IMA200 series, IMA204, is directed 
      at the novel tumor stroma target COL6A3 exon 6 expressed in a large 
      variety of solid cancers. IMA204 is utilizing a next-generation 
      CD8-independent T cell receptor. Following a scientific advice meeting2 
      with Paul-Ehrlich-Institute (PEI) in May, the Federal German regulatory 
      authority, submission of a clinical trial application (CTA) remains on 
      track for Q4 2021. 
 
 
   https://www.globenewswire.com/Tracker?data=qMZIvZqxTAyp_TILwdTXSebpsdcOzFHj-_T2nOmABwyoR8fvrj6jbyB4AO6LqGKwbw_kCiYSU3fgUKwe3wzFUvTNw-KGxu8Cccf07o3GvAA6Vvee_GGliBrCICgDzDyF 
TCR Bispecifics Programs 
 
 
   -- IMA402 -- Immatics provided preclinical proof-of-concept data 
      https://investors.immatics.com/news-releases/news-release-details/immatics-presents-preclinical-proof-concept-data-tcr-0 
      for 
      https://investors.immatics.com/news-releases/news-release-details/immatics-presents-preclinical-proof-concept-data-tcr-0 
      its second TCER(R) program, IMA402 
      https://investors.immatics.com/news-releases/news-release-details/immatics-presents-preclinical-proof-concept-data-tcr-0 
      , at the Annual PEGS Boston Protein Engineering and Cell Therapy Summit 
      in May. The IMA402 candidate targets an Immatics-validated peptide 
      derived from PRAME, a protein that is frequently expressed in many solid 
      cancers, thereby supporting the program's potential to address a broad 
      cancer patient population. IMA402 demonstrated tumor cell killing in 
      vitro and lead to consistent tumor reduction including complete 
      regression of established tumors in an in vivo mouse model. Immatics has 
      selected a clinical lead candidate for the IMA402 program and initiated 
      manufacturing activities to advance this program towards the 
      Investigational New Drug (IND) stage and clinical development. 
 
   -- The company's first TCER(R) program, IMA401 remains on track for 
      submission of a clinical trial application (CTA) by year end 2021. The 
      company had announced preclinical proof-of-concept data for IMA401 
      https://investors.immatics.com/news-releases/news-release-details/immatics-presents-preclinical-proof-concept-data-tcr-bispecifics 
      in last quarter of 2020. 
 
 
   First Quarter 2021 Financial Results 
 
   Cash Position: Cash and cash equivalents as well as other financial 
assets total EUR216.7 million ($254.0 million(1) ) as of March 31, 2021. 
compared to EUR232.0 million ($272.0 million(1) ) as of December 31, 
2020. 
 
   Revenue: Total revenue, consisting of revenue from collaboration 
agreements, was EUR7.4 million ($8.7 million(1) ) for the three months 
ended March 31, 2021, compared to EUR7.0 million ($8.2 million(1) ) for 
the three months ended March 31, 2020. 
 
   Research and Development Expenses: R&D expenses were EUR23.0 million 
($27.0 million(1) ) for the three months ended March 31, 2021, compared 
to EUR12.2 million ($14.4 million(1) ) for the three months ended March 
31, 2020. The increase is mainly due to increased share-based 
compensation (EUR4.5 million; $5.3 million(1) ) as well as higher 
operating expenses due to increased clinical and manufacturing 
activities. 
 
   General and Administrative Expenses: G&A expenses were EUR8.4 million 
($9.9 million(1) ) for the three months ended March 31, 2021, compared 
to EUR6.2 million ($7.3 million(1) ) for the three months ended March 
31, 2020. The increase is mainly due to increased share-based 
compensation (EUR3.1 million; $3.7 million(1) ), partly offset by 
one-time transaction costs of the NASDAQ listing in connection with the 
ARYA merger in July 2020. 
 
   Net Loss: Net loss was EUR21.6 million ($25.3 million(1) ) for the three 
months ended March 31, 2021, compared to EUR8.6 million ($10.1 
million(1) ) for the three months ended March 31, 2020. 
 
   Upcoming Investor Conferences 
 
 
   -- Jefferies Virtual Healthcare Conference -- June 1-3, 2021 
 
   -- Goldman Sachs 42nd Annual Global Healthcare Conference -- June 8-11, 2021 
 
   To see the full list of events and presentations, visit 
www.investors.immatics.com/events-presentations. 
 
   Full financial statements can be found in the current report on Form 6-K 
filed with the Securities and Exchange Commission (SEC) and published on 
the SEC website under https://www.sec.gov/. 
 
   (1) All amounts translated using the exchange rate published by the 
European Central Bank in effect as of March 31, 2021 (1 EUR = 1.1725 
USD). 
 
   (2) Equivalent to a pre-IND meeting at FDA. 
 
   About ACTengine(R) IMA200 series 
 
   Each of the product candidates of the IMA200 series is based on 
Immatics' proprietary ACTengine(R) approach in which the patient's own T 
cells are genetically engineered to express a novel, proprietary TCR 
directed against a defined cancer target. The modified T cells are then 
reinfused into the patient to attack the tumor, an approach also known 
as TCR-T. ACTengine(R) programs IMA201, IMA202 and IMA203 are currently 
in clinical development for the treatment of solid tumor indications, 
both in the US and in Germany. All ACTengine(R) product candidates can 
be rapidly manufactured utilizing a proprietary manufacturing process 
designed to enhance T cell engraftment and persistence in vivo. 
 
   The ACTengine(R) T cell products are manufactured at the Evelyn H. 
Griffin Stem Cell Therapeutics Research Laboratory in collaboration with 
UTHealth and co-funded by the Cancer Prevention and Research Institute 
of Texas (CPRIT). 
 
   About TCER(R) 
 
   Immatics' TCER(R) molecules are antibody-like "off-the-shelf" biologics 
that leverage the body's immune system by redirecting and activating T 
cells towards cancer cells expressing a specific tumor target. To do so, 
the proprietary biologics are engineered to have two binding regions. 
The first region contains an affinity- and stability-improved TCR that 
binds specifically to the cancer target on the cell surface presented by 
a human leukocyte antigen (HLA) molecule. The second region is derived 
from an antibody domain that recruits endogenous T cells to the tumor to 
become activated. The design of the TCER(R) molecules enables the 
activation of any T cell in the body to attack the tumor, regardless of 
the T cells' intrinsic specificity. In addition, the TCER(R) molecule

(MORE TO FOLLOW) Dow Jones Newswires

May 18, 2021 07:00 ET (11:00 GMT)